# S 511

RU-486 Suspension and Review Act of 2005

**Congress:** 109 (2005–2007, Ended)
**Chamber:** Senate
**Policy Area:** Health
**Introduced:** Mar 3, 2005
**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure
**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2020-2021) (Mar 3, 2005)
**Official Text:** https://www.congress.gov/bill/109th-congress/senate-bill/511

## Sponsor

**Name:** Sen. DeMint, Jim [R-SC]
**Party:** Republican • **State:** SC • **Chamber:** Senate

## Cosponsors (12 total)

| Cosponsor | Party / State | Role | Date Joined |
|---|---|---|---|
| Sen. Allen, George [R-VA] | R · VA | | Mar 3, 2005 |
| Sen. Brownback, Sam [R-KS] | R · KS | | Mar 3, 2005 |
| Sen. Coburn, Tom [R-OK] | R · OK | | Mar 3, 2005 |
| Sen. Ensign, John [R-NV] | R · NV | | Mar 3, 2005 |
| Sen. Enzi, Michael B. [R-WY] | R · WY | | Mar 3, 2005 |
| Sen. Inhofe, James M. [R-OK] | R · OK | | Mar 3, 2005 |
| Sen. Santorum, Rick [R-PA] | R · PA | | Mar 3, 2005 |
| Sen. Vitter, David [R-LA] | R · LA | | Mar 3, 2005 |
| Sen. Bunning, Jim [R-KY] | R · KY | | Jul 11, 2005 |
| Sen. Thune, John [R-SD] | R · SD | | Sep 7, 2005 |
| Sen. DeWine, Mike [R-OH] | R · OH | | Sep 21, 2005 |
| Sen. Martinez, Mel [R-FL] | R · FL | | May 2, 2006 |

## Committee Activity

| Committee | Chamber | Activity | Date |
|---|---|---|---|
| Health, Education, Labor, and Pensions Committee | Senate | Referred To | Mar 3, 2005 |

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

| Bill | Relationship | Last Action |
|---|---|---|
| 109 HR 1079 | Related bill | **Mar 14, 2005:** Referred to the Subcommittee on Health. |

## Summary (as of Mar 3, 2005)

RU-486 Suspension and Review Act of 2005 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.

Deems the drug misoprostol as misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.

Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.

## Actions Timeline

- **Mar 3, 2005:** Introduced in Senate
- **Mar 3, 2005:** Sponsor introductory remarks on measure. (CR S2020)
- **Mar 3, 2005:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2020-2021)